temozolomide has been researched along with hes1 protein, human in 2 studies
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 0 (0.00) | 18.2507 |
| 2000's | 0 (0.00) | 29.6817 |
| 2010's | 1 (50.00) | 24.3611 |
| 2020's | 1 (50.00) | 2.80 |
| Authors | Studies |
|---|---|
| Chuang, SE; Hu, TS; Lai, GM; Lai, IC; Lai, TY; Lui, TN; Shih, PH; Wang-Peng, J; Yao, CJ; Yeh, CT | 1 |
| Fei, M; Niu, W; Tang, T; Wang, H; Zhang, L; Zhu, Y | 1 |
2 other study(ies) available for temozolomide and hes1 protein, human
| Article | Year |
|---|---|
Elimination of cancer stem-like cells and potentiation of temozolomide sensitivity by Honokiol in glioblastoma multiforme cells.
Topics: Antineoplastic Agents; Apoptosis; Basic Helix-Loop-Helix Transcription Factors; Biphenyl Compounds; Brain Neoplasms; Cell Proliferation; Dacarbazine; Dose-Response Relationship, Drug; Down-Regulation; Drug Synergism; Drug Therapy, Combination; Glioblastoma; Homeodomain Proteins; Humans; Lignans; Neoplastic Stem Cells; Receptor, Notch3; Receptors, Notch; Temozolomide; Transcription Factor HES-1; Tumor Cells, Cultured | 2015 |
Smarcd1 Inhibits the Malignant Phenotypes of Human Glioblastoma Cells via Crosstalk with Notch1.
Topics: Animals; Apoptosis; Brain Neoplasms; Cell Cycle Checkpoints; Cell Line, Tumor; Cell Movement; Cell Proliferation; Chromosomal Proteins, Non-Histone; Down-Regulation; G1 Phase; Gene Expression Regulation, Neoplastic; Glioblastoma; Humans; Male; Mice, Inbred BALB C; Mice, Nude; Neoplasm Invasiveness; Phenotype; Receptor, Notch1; Signal Transduction; Temozolomide; Transcription Factor HES-1; Transcription, Genetic; Tumor Suppressor Protein p53 | 2021 |